Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects-Reference-Cited by-同舟云学术

Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects

Published:2020-08 Issue:2 Volume:86 Page:307-314
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Ogasawara Ken,Xu Christine,Kanamaluru Vanaja,Siebers Nicholas,Surapaneni Sekhar,Ridoux Laurence,Palmisano Maria,Krishna Gopal^ORCID

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-020-04121-0.pdf

Reference17 articles.

1. Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129(6):667–679. https://doi.org/10.1182/blood-2016-10-695940

2. Tefferi A (2016) Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 91(12):1262–1271. https://doi.org/10.1002/ajh.24592

3. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (2014) Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 92(4):289–297. https://doi.org/10.1111/ejh.12256

4. Celgene Corporation (2019) Inrebic (fedratinib) [package insert]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf. Accessed 11 Apr 2020

5. Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y (2019) Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer Chemother Pharmacol 84(4):891–898. https://doi.org/10.1007/s00280-019-03929-9

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19;Cancer Chemotherapy and Pharmacology;2024-08-07

2. A gastrointestinal locally activating Janus kinase inhibitor to treat ulcerative colitis;Journal of Biological Chemistry;2023-12

3. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis;Expert Opinion on Pharmacotherapy;2022-10-13

4. Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs;Current Medicinal Chemistry;2022-09

5. Recent advances in metabolism and toxicity of tyrosine kinase inhibitors;Pharmacology & Therapeutics;2022-09